Foamix (FOMX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 8, 2018 4:01 PM EDTREHOVOT, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (Foamix or the Company), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today its financial results for the second quarter and six months ended June 30, 2018.
Clinical and Corporate Update:
The final patient was enrolled and dosed in the third Phase 3 study (FX2017-22) investigating FMX101, the Companys minocycline foam 4%, in patients with moderate-to-severe acne.- Top-line results are expected in... More